NeuroSense Therapeutics (NRSNW) Competitors $0.08 +0.01 (+10.27%) As of 03:36 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock NRSNW vs. AIMDW, ALVOW, ARAV, ACABW, and RNAShould you buy NeuroSense Therapeutics stock or one of its competitors? MarketBeat compares NeuroSense Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeuroSense Therapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. NRSNW vs. AIMDWNRSNW vs. ALVOWNRSNW vs. ARAVNRSNW vs. ACABWNRSNW vs. RNAHow does NeuroSense Therapeutics compare to Ainos?NeuroSense Therapeutics (NASDAQ:NRSNW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings. Is NRSNW or AIMDW more profitable? Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A N/A Ainos N/A N/A N/A Which has better earnings and valuation, NRSNW or AIMDW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/AN/AN/AN/AAinos$18.11KN/AN/AN/AN/A Does the media refer more to NRSNW or AIMDW? In the previous week, Ainos had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 1 mentions for Ainos and 0 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.00 equaled Ainos'average media sentiment score. Company Overall Sentiment NeuroSense Therapeutics Neutral Ainos Neutral SummaryAinos beats NeuroSense Therapeutics on 2 of the 2 factors compared between the two stocks.How does NeuroSense Therapeutics compare to Alvotech?Alvotech (NASDAQ:ALVOW) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings. Does the media refer more to ALVOW or NRSNW? In the previous week, Alvotech's average media sentiment score of 0.00 equaled NeuroSense Therapeutics'average media sentiment score. Company Overall Sentiment Alvotech Neutral NeuroSense Therapeutics Neutral Is ALVOW or NRSNW more profitable? Company Net Margins Return on Equity Return on Assets AlvotechN/A N/A N/A NeuroSense Therapeutics N/A N/A N/A Which has stronger valuation and earnings, ALVOW or NRSNW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlvotech$586.32MN/AN/AN/AN/ANeuroSense TherapeuticsN/AN/AN/AN/AN/A SummaryAlvotech beats NeuroSense Therapeutics on 1 of the 1 factors compared between the two stocks.How does NeuroSense Therapeutics compare to Aravive?Aravive (NASDAQ:ARAV) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Do insiders and institutionals believe in ARAV or NRSNW? 35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has better valuation & earnings, ARAV or NRSNW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAraviveN/AN/AN/A-$0.90N/ANeuroSense TherapeuticsN/AN/AN/AN/AN/A Does the media favor ARAV or NRSNW? In the previous week, Aravive's average media sentiment score of 0.00 equaled NeuroSense Therapeutics'average media sentiment score. Company Overall Sentiment Aravive Neutral NeuroSense Therapeutics Neutral Is ARAV or NRSNW more profitable? Company Net Margins Return on Equity Return on Assets AraviveN/A N/A N/A NeuroSense Therapeutics N/A N/A N/A SummaryAravive beats NeuroSense Therapeutics on 2 of the 2 factors compared between the two stocks.How does NeuroSense Therapeutics compare to Atlantic Coastal Acquisition Corp. II?Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Is ACABW or NRSNW more profitable? Company Net Margins Return on Equity Return on Assets Atlantic Coastal Acquisition Corp. IIN/A N/A N/A NeuroSense Therapeutics N/A N/A N/A Which has preferable valuation and earnings, ACABW or NRSNW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/ANeuroSense TherapeuticsN/AN/AN/AN/AN/A Does the media refer more to ACABW or NRSNW? In the previous week, Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.00 equaled NeuroSense Therapeutics'average media sentiment score. Company Overall Sentiment Atlantic Coastal Acquisition Corp. II Neutral NeuroSense Therapeutics Neutral SummaryAtlantic Coastal Acquisition Corp. II and NeuroSense Therapeutics tied by winning 0 of the 0 factors compared between the two stocks.How does NeuroSense Therapeutics compare to Avidity Biosciences?NeuroSense Therapeutics (NASDAQ:NRSNW) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment. Do analysts rate NRSNW or RNA? Avidity Biosciences has a consensus target price of $69.42, suggesting a potential upside of 436.07%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than NeuroSense Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Avidity Biosciences 1 Sell rating(s) 11 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.37 Which has preferable valuation & earnings, NRSNW or RNA? NeuroSense Therapeutics has higher earnings, but lower revenue than Avidity Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/AN/AN/AN/AAvidity Biosciences$36.68M6.04-$322.30MN/AN/A Does the media refer more to NRSNW or RNA? In the previous week, Avidity Biosciences had 5 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 5 mentions for Avidity Biosciences and 0 mentions for NeuroSense Therapeutics. Avidity Biosciences' average media sentiment score of 0.80 beat NeuroSense Therapeutics' score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Overall Sentiment NeuroSense Therapeutics Neutral Avidity Biosciences Positive Is NRSNW or RNA more profitable? NeuroSense Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. NeuroSense Therapeutics' return on equity of 0.00% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A N/A Avidity Biosciences -3,650.39%-44.92%-39.57% SummaryAvidity Biosciences beats NeuroSense Therapeutics on 7 of the 10 factors compared between the two stocks. Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSNW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRSNW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRSNW vs. The Competition ExportMetricNeuroSense TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$465.73M$6.25B$12.23BDividend YieldN/A3.87%2.80%5.32%P/E RatioN/A3.7620.7925.05Price / SalesN/A7,435.94531.2172.69Price / CashN/A13.1343.0954.25Price / BookN/A83.539.816.83Net IncomeN/A-$96.07M$3.55B$335.69M7 Day PerformanceN/A0.52%-2.07%-2.03%1 Month PerformanceN/A0.18%-3.90%-1.90%1 Year PerformanceN/A71.17%29.39%27.36% NeuroSense Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRSNWNeuroSense TherapeuticsN/A$0.08+10.3%N/A-26.0%$0.00N/AN/A10AIMDWAinosN/A$0.08+15.9%N/A-54.3%$0.00$124.16KN/A40News CoverageALVOWAlvotechN/A$0.25flatN/A-87.9%$0.00$586.32MN/A4Gap UpARAVAraviveN/A$0.04flatN/AN/A$0.00N/AN/A20High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.00flatN/AN/A$0.00N/AN/A15 Related Companies and Tools Related Companies AIMDW Competitors ALVOW Competitors ARAV Competitors ACABW Competitors RNA Competitors BFRIW Competitors CELUW Competitors CINGW Competitors CMRAW Competitors DRMAW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRSNW) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
